Inclusion Criteria:

- Patients must be > 18 years of age, with no upper age limit.

- Patients must have an ECOG performance status of 0 or 1.

- Any patient with a hematologic malignancy which is unlikely to be cured by
conventional treatment is eligible for this study.

- Patients for whom a disease specific protocol exists will be transplanted on those
protocols as discussed in the introduction.

- Patients who have had prior autografts may be treated on this protocol.

- Patients must have adequate physical function as measured by the following criteria:

- Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at
rest must be >40%.

- Hepatic: AST micro 3x the upper limits of normal and total serum bilirubin < 2.5
mg/dL. Patients with a higher bilirubin from "benign conditions" such as Gilbert's
disease may still be eligible for the study.

- Renal: Serum creatinine within the normal range or if creatinine outside normal range
then creatinine clearance > 60 ml/min/1.73m2. Serum creatinine must be less than or
equal to 2.0 mg/dl.

- Pulmonary: Asymptomatic or, if symptomatic, DLCO (diffusion capacity) > 45% of
predicted (corrected for hemoglobin)

- The patient or guardian(s) must be able to give informed consent to the study.

- Patient must have a suitable donor who is identical for HLA-A, -B, -C, - DR. Single
antigen mismatches for HLA-A, -B, -C, -DR are also permitted. Donors obtained through
the NMDP will follow NMDP guidelines.

Exclusion Criteria:

- Patients who are eligible for a standard myeloablative transplant and for whom a
standard myeloablative transplant is preferable will not be treated on this protocol.